Back
Introducing Project AIR
webCredibility Rating
4/5
High(4)High quality. Established institution or organization with editorial oversight and accountability.
Rating inherited from publication venue: Blueprint Biosecurity
Project AIR is a Blueprint Biosecurity initiative addressing the biosecurity risks posed by advanced AI systems, particularly the potential for AI to lower barriers to developing or deploying biological weapons—a concern highlighted in major AI safety discussions.
Metadata
Importance: 52/100organizational reporthomepage
Summary
Blueprint Biosecurity's Project AIR is an initiative focused on preparing for and responding to biological risks that may be enabled or accelerated by artificial intelligence. The project aims to develop frameworks and capabilities for identifying, assessing, and mitigating AI-related biosecurity threats before they materialize.
Key Points
- •Project AIR addresses the intersection of AI capabilities and biosecurity, focusing on risks where AI could enable or accelerate biological threats
- •Blueprint Biosecurity is a biosecurity-focused nonprofit working at the AI-biosecurity nexus
- •The initiative likely involves developing response protocols and early warning systems for AI-enabled biorisks
- •Represents an applied governance and policy effort to bridge AI safety and biosecurity communities
- •Focuses on proactive risk mitigation rather than reactive measures after incidents occur
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| Blueprint Biosecurity | Organization | 60.0 |
Cached Content Preview
HTTP 200Fetched Mar 15, 20267 KB
Introducing the AIR Program – Blueprint Biosecurity
Programs
Far-UVC
PPE
Glycol vapors
Funded Projects
Calls for Proposals
Publications
News
Team
Careers
Contact
Copyright © 2026 Blueprint Biosecurity - All Rights Reserved.
Privacy Policy & Cookies
Back
03/31/25
Introducing the AIR Program
Delivering a breakthrough against airborne disease
Written by The AIR Team
far-UVC
Project AIR
Share on :
The Airborne Infection Resilience (AIR) program is a five-year research initiative focused on speeding up the widespread adoption of far-UVC —a breakthrough technology for combatting airborne disease.
Accelerating Far-UVC Research and Adoption
Commercial far-UVC devices are available but deployed at a very limited scale. Several critical barriers are hindering the widespread adoption required to meaningfully reduce airborne disease and keep us safe from novel pandemics:
Scientific validation requires additional real-world evidence
Optimal installation designs are still being determined
Full characterization of biological effects is incomplete
Clear deployment guidelines backed by research are needed
Cost reduction through technological improvement is necessary
Goals and Structure
AIR aims to address three critical bottlenecks preventing global scale-up:
Secure endorsements from global public health agencies
Develop real-world guidance for precise far-UVC implementation
Catalyze multinational public and private funding to support rollout
The program is structured into three primary workstreams:
Workstream 1: Randomized Controlled Trial
Conduct the first large-scale RCT of far-UVC effectiveness in approximately 50 real-world settings
Perform controlled bioaerosol chamber studies and computational fluid dynamics modeling
Workstream 2: Safety Studies
Verify far-UVC exposure limits through multiple human and animal studies
Measure indoor air chemistry effects across diverse environments
Build scientific consensus around safety parameters
Workstream 3: Consensus and Deployment Guidance
Develop evidence-based implementation protocols for diverse settings
Create educational materials and evaluate communication strategies
Initiate a National Academies consensus study to serve as a trusted, objective authority
Our Persistent Vulnerability to Airborne Disease
Despite remarkable advances in controlling water-borne, food-borne, and vector-borne diseases, airborne infectious diseases remain one of humanity’s most significant public health challenges. COVID-19 has caused over 27 million deaths globally , while tuberculosis and seasonal influenza continue to exact a devastating toll, 1.6 million and 700
... (truncated, 7 KB total)Resource ID:
0eb11fa48a842311 | Stable ID: N2E3M2NkND